About this trial
Purpose
The primary aim of this research project is to evaluate whether a special blanket is an effective intervention for improving sleep among young people aged 16-24 with sleep disturbances. Sleep problems are increasingly common among Danish youth, with approximately one in five reporting significant sleep difficulties in the past 14 days. This trend has been rising steadily since 2010 and is mirrored internationally. Sleep disturbances are linked to a wide range of physical and mental health problems, including stress, anxiety, and depression, as well as negative effects on academic performance and social relationships. Early intervention is crucial to prevent chronic insomnia and poor mental health outcomes in adulthood.
Current treatments include specialized psychological therapies and medication. However, psychological therapies require extensive time and commitment, and medication carries risks of side effects, tolerance, and dependency, making non-pharmacological, safe, and accessible alternatives necessary. The special blanket is believed to promote relaxation through stimulation of the tactile and proprioceptive systems. Although promising in clinical and pedagogical contexts for certain populations (e.g., children with developmental disorders and adults with neurological conditions), there is limited scientific evidence regarding its efficacy and underlying mechanisms, particularly among youth with sleep disturbances.
Methods and Study Design
This project is a Phase 1 randomized controlled trial (RCT) assessing the effect of 4 weeks of using a special blanket on sleep problems among young people aged 16-24, as well as the impact on participants' mental and physical health. Additionally, the study investigates possible stress-related mechanisms involved in the use of the special blanket. Following the 4-week intervention, an open-label extension phase of 8 weeks (Phase 2) will explore continued use and acceptability of the blanket.
Eligible participants, screened for sleep problems, will be randomly assigned to one of three groups:
Group 1: receives a special blanket (Blanket A) for home use over 4 weeks.
Group 2: receives another special blanket (Blanket B) for 4 weeks.
Group 3 (observation group): no blanket provided but followed for 4 weeks to monitor changes in sleep problems.
The 4-week intervention phase (Phase 1) includes baseline (T1, week 0), mid-intervention (T2, week 2), and post-intervention (T3, week 4) online assessments. Sleep disturbances, physical and mental health, and stress-related mechanisms will be measured using validated questionnaires administered through REDCap. The first 40 participants in Groups 1 and 2 will additionally provide saliva samples and wear a circadian rhythm monitor (activity watch).
In Phase 2, participants in Groups 1 and 2 may continue using the blanket or revert to their usual bedding. At the end of Phase 2 (T4, week 12), follow-up questionnaires will assess sleep and user experience, including satisfaction, perceived benefits, barriers, and drawbacks of the blanket. Group 3 will then be offered a special blanket for an 8-week trial.
Participants The investigators aim to recruit 672 young people aged 16-24 with sleep problems.
Inclusion criteria are age 16-24 years and sleep problems measured by Insomnia Severity Index (score \>10). Exclusion criteria are any underlying somatic, psychological, or neurological condition significantly affecting sleep quality; use of medications affecting sleep; pregnancy; shift work or night work; previous use of special blankets for sleep improvement and insufficient Danish language skills (questionnaires in Danish).
Significance and Relevance
The investigators anticipate that the findings will contribute to the current understanding of the non-pharmacological management of sleep problems, related mental and physical health outcomes, and underlying stress-related mechanisms of special blanket interventions. The results will be relevant to health professionals working with sleep problems, but also to adolescents and younger adults with sleep problems and their parents. New clinical guidelines on sleep problems in children and adolescents recommend non-pharmacological treatments as the first choice, specifically mentioning the potential efficacy of special blankets. The proposed project will help inform further development of such guidelines and related clinical practice. If special blankets are found to be effective in reducing insomnia, they could serve as an inexpensive, easily disseminated, and administered treatment with no known side effects, with the potential to greatly reduce the personal, as well as societal costs of insomnia.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Participants must be between 16 and 24 years old
Participants must have a score on the Insomnia Severity Index (ISI) above 10.
Disqualifiers
Presence of neurological disorders known to influence or be related to poor sleep including affective disorders and diagnosed medical sleep disorders (e.g., sleep apnea, narcolepsy)
Circulatory or respiratory disease
Pregnancy, shift or night work
Prior use of special blanket (within the past five years)
Trial design
Parallel
Treatments tested in this trial
Special blanket
DeviceSpecial blanket to be used at home every night in 4 weeks (Phase 1 - RCT) and opportunity for additional 8 weeks (Phase 2 - open trial)
Different special blanket
DeviceDifferent special blanket to be used at home every night in 4 weeks (Phase 1 - RCT) and opportunity for additional 8 weeks (Phase 2 - open trial)
Treatment groups
Trial outcomes
Primary outcomes
Insomnia Severity
Insomnia Severity Index (ISI) will be used to assess the severity of insomnia symptoms. The ISI is a brief self-report instrument consisting of seven items that evaluates the severity of sleep-onset, sleep maintenance, early morning awakening problems, satisfaction with current sleep pattern, interference with daily functioning, noticeability of impairment attributed to the sleep problem, and level of distress caused by the sleep problem. This corresponds in part to the diagnostic criteria of insomnia. Zero is the minimum value and equivalent to no insomnia and 28 is the maximum value and indicates clinical insomnia in severe degree.
Secondary outcomes
The Pittsburgh Sleep Quality Index
The Pittsburg Sleep Quality Index (PSQI) will be used in order to measure subjective sleep quality. It consists of 19 self-rated items and has high internal consistency (Cronbach's α = 0.83) and test-retest reliability (r = 0.85). The minimum score is 0 and the maximum score is 21, with higher scores indicating poorer sleep quality.
Actigraphy-based sleep
ActTrust 1 (Condor Instruments, São Paulo, Brazil) will be used to measure rest/wake activity for 8 days at two timepoints in a subgroup (n=80). In addition to sleep/wake activity, ActTrust records information about amount and duration of ambient light and wrist temperature, allowing analyses of whether observed effects are related to group-differences in temperature. Extracted sleep variables include sleep onset latency (SOL), total sleep time (TST), sleep efficiency (SE), and wake after sleep onset (WASO). To help edit actigraphy data, participants will complete a sleep diary during this period, giving information about bedtime, time spent falling asleep, wake up time, rise time, estimated number of awakenings and self-rated sleep quality.
Diurnal salivary cortisol
Diurnal salivary cortisol will be measured in a subgroup of participants (n = 80, 40 from each of groups 1 and 2) at two different time points. At each of these time points, participants will be instructed in home-based self-collection of 5 daily saliva samples for two consecutive days. The daily samples will be collected at personal waking (#1); 30 min. after waking (#2); 45 min. after waking (#3); between 4 and 6pm (#4); and at bedtime (#5). This sampling schedule allows for the assessment of both diurnal cortisol patterns and Cortisol Awakening Response (CAR) estimation. Samples will be collected in labelled Sarstedt salivettes and stored in sealable dark plastic bags to protect from sun exposure. Collection time will be written on the salivette by participants.
Stress
The Perceived Stress Scale (PSS) is a classic stress assessment instrument. Individual scores on the PSS can range from 0 to 40 with higher scores indicating higher perceived stress. * Scores ranging from 0-13 would be considered low stress. * Scores ranging from 14-26 would be considered moderate stress. * Scores ranging from 27-40 would be considered high perceived stress.
Sponsors and contacts
Click on the lead sponsor to view all of their trials.
Aarhus University Hospital
Lead sponsor
University of Aarhus
Sponsor institution
University of Aarhus
Collaborator